Nautilus Biotechnology (NAUT) Invested Capital (2020 - 2026)

Nautilus Biotechnology has disclosed Invested Capital across 7 years of filings, most recently posting $144.4 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $144.4 million, down 25.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.4 million (down 25.73% YoY), and the FY2025 annual result was $157.0 million, down 24.8% from the prior year.
• Invested Capital came in at $144.4 million for Q1 2026 at Nautilus Biotechnology, down from $157.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $349.7 million in Q1 2022 to a low of $144.4 million in Q1 2026.
• The 5-year median for Invested Capital is $249.5 million (2024), against an average of $248.6 million.
• Across the five-year window, Invested Capital surged 1051.2% in 2022 and slipped 25.73% in 2026, its largest moves.
• Nautilus Biotechnology's Invested Capital stood at $314.9 million in 2022, then decreased by 15.74% to $265.4 million in 2023, then fell by 21.34% to $208.7 million in 2024, then fell by 24.8% to $157.0 million in 2025, then dropped by 8.0% to $144.4 million in 2026.
• The last three Invested Capital figures came in at $144.4 million (Q1 2026), $157.0 million (Q4 2025), and $169.1 million (Q3 2025), per Business Quant data.